Shanghai, China2021.6.21
QureBio, invested and incubated by Viva BioInnovator, who is dedicated to the development of innovative macromolecular biological drugs with independent intellectual property rights, announced that its phase I clinical trial of Q-1802 (Claudin18.2 / PD-L1) bispecific antibody in the treatment of advanced solid tumors successfully completed its first patient enrollment in Luzhong Hospital of Peking University
Medical University.The phase I multicenter clinical trial was led by Shen Lin, President of Peking University Cancer Hospital, to evaluate the safety, tolerance and pharmacokinetics of Q-1802 in patients with advanced solid tumors. The study was also carried out in Fudan University Cancer Hospital, West China Second Hospital of Sichuan University and Luzhong hospital of Peking University Medical University.
